# Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

> **NCT01231685** · PHASE2 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 9 (actual)

## Conditions studied

- HIV
- Hepatitis C
- Liver Fibrosis

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Ritonavir-boosted protease inhibitor

## Key facts

- **NCT ID:** NCT01231685
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2016-09-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231685, "Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01231685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*